三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
赛沃替尼vs竞品:治疗EGFR-TKI耐药NSCLC的疗效及安全性
赛沃替尼vs竞品:治疗EGFR-TKI耐药NSCLC的疗效及安全性
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:194KB
图片尺寸:2298*805
同报告图片
/
4
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
fCDlubTku70gfCDoh6rmnInlm6LpmJ/plIDllK7kuqflk4HvvIjnmb7kuIfnvo7lhYPvvIkgfCDlhbbku5bkuJrliqHvvIjnmb7kuIfnvo7lhYPvvIkgfCDogr/nmKQv5YWN55ar5Lqn5ZOB6LS555So546H77yI5Y+z6L2077yJIHwg5YW25LuW5Lia5Yqh6LS555So546H77yI5Y+z6L2077yJIHwKfC0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgMjAyMSB8IDIwICAgICAgICAgICAgICAgICAgICAgICB8IDEwICAgICAgICAgICAgICAgICAgIHwgODUlICAgICAgICAgICAgICAgICAgICAgIHwgMjAlICAgICAgICAgICAgICAgICAgfAp8IDIwMjIgfCAzMCAgICAgICAgICAgICAgICAgICAgICAgfCA1ICAgICAgICAgICAgICAgICAgICB8IDgwJSAgICAgICAgICAgICAgICAgICAgICB8IDE1JSAgICAgICAgICAgICAgICAgIHwKfCAyMDIzIHwgNDAgICAgICAgICAgICAgICAgICAgICAgIHwgNSAgICAgICAgICAgICAgICAgICAgfCA5MCUgICAgICAgICAgICAgICAgICAgICAgfCAxMCUgICAgICAgICAgICAgICAgICB8CnwgMjAyNEV8IDUwICAgICAgICAgICAgICAgICAgICAgICB8IDUgICAgICAgICAgICAgICAgICAgIHwgODAlICAgICAgICAgICAgICAgICAgICAgIHwgMTAlICAgICAgICAgICAgICAgICAgfAp8IDIwMjVFfCA2MCAgICAgICAgICAgICAgICAgICAgICAgfCA1ICAgICAgICAgICAgICAgICAgICB8IDcwJSAgICAgICAgICAgICAgICAgICAgICB8IDEwJSAgICAgICAgICAgICAgICAgIHwKfCAyMDI2RXwgODAgICAgICAgICAgICAgICAgICAgICAgIHwgNSAgICAgICAgICAgICAgICAgICAgfCA3MCUgICAgICAgICAgICAgICAgICAgICAgfCAxMCUgICAgICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJpXaW5k77yM5YWs5Y+45bm05oql77yM5Y2O5rOw56CU56m26aKE5rWL
所属报告:
和黄医药-港股公司研究报告-蓝海扬帆行致远海外市场启新程-241230(57页).pdf
打包全文图表
相关数据
ADC联合IO单抗治疗一线NSCLC全球三期研究启动时间
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
收藏
行业数据
2026-07-14
原图定位
查看详情
KRASG12C一线治疗NSCLC竞争格局(截至2026-6-25)
收藏
竞争格局
2026-07-01
原图定位
查看详情
全球KRASG12C突变的NSCLC发病人数
收藏
行业数据
2026-07-01
原图定位
查看详情
中国KRASG12C突变的NSCLC发病人数
收藏
行业数据
2026-07-01
原图定位
查看详情
ZG006临床2期研究的安全性数据(10mg剂量)
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
收藏
行业数据
2026-06-26
原图定位
查看详情
ZG006临床2期研究的安全性数据(30mg剂量)
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
收藏
行业数据
2026-06-26
原图定位
查看详情
SHR-A2009用于EGFR突变型NSCLC的1期临床研究结果
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
收藏
行业数据
2026-05-28
原图定位
查看详情
SHR-A2009用于一线NSCLC患者的研究结果
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
收藏
行业数据
2026-05-28
原图定位
查看详情
2020-2034E中国非临床安全性评价市场规模(亿美元)
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
收藏
市场规模
2026-05-25
原图定位
查看详情
临床数据显示国产厂商有效性安全性比肩达芬奇
收藏
行业数据
2026-04-27
原图定位
查看详情
食品安全监管模式全链条、全周期、全要素系统性治理升级
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
收藏
商业模式
2026-04-03
原图定位
查看详情
Ph2a临床研究Sefaxersen尿蛋白及eGFR数据
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
收藏
行业数据
2026-03-13
原图定位
查看详情
Ph3NeflgArd研究第24个月eGFR及uPCR数据
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
收藏
行业数据
2026-03-13
原图定位
查看详情
PD(L)1*VEGF双抗单药针对一线NSCLC数据汇总
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
收藏
行业数据
2026-03-13
原图定位
查看详情
Ph1/2ADU-CL-19研究中Zigakibart组受试者100周uPCR及eGFR数据
fCBXZWVrIHwgdVBDUu+8iCXlj5jljJbvvIkgfCB1UENSIG4gfCBlR0ZS77yIJeWPmOWMlu+8iSB8IGVHRlIgbiB8CnwtLS0tLS18LS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLXwKfCA0ICAgIHwgLTYuMSAgICAgICAgICB8IDM0ICAgICB8IDAuNyAgICAgICAgICAgfCAzMyAgICAgfAp8IDEyICAgfCAtMTkuNSAgICAgICAgIHwgMzMgICAgIHwgMi4zICAgICAgICAgICB8IDM0ICAgICB8CnwgMjggICB8IC0zMy43ICAgICAgICAgfCAzNCAgICAgfCAxLjUgICAgICAgICAgIHwgMzMgICAgIHwKfCA1MiAgIHwgLTUzLjQgICAgICAgICB8IDM1ICAgICB8IDIuMCAgICAgICAgICAgfCAzNCAgICAgfAp8IDc2ICAgfCAtNTguMyAgICAgICAgIHwgMzIgICAgIHwgMi44ICAgICAgICAgICB8IDM0ICAgICB8CnwgMTAwICB8IC02MC40ICAgICAgICAgfCAyOSAgICAgfCAzLjYgICAgICAgICAgIHwgMzAgICAgIHwKCui1hOaWmeadpea6kO+8mktpZG5leSBJbnRlcm5hdGlvbmFsLCDlm73kv6Hor4HliLjnu4/mtY7noJTnqbbmiYDmlbTnkIY=
收藏
行业数据
2026-03-13
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
a)埃万妥单抗三药方案全人群 DoR 及 PFS 较低,联合兰泽替尼的四药方案虽然 PFS更长但不良反应明显升高;b)PD-1+VEGF 单抗联合或双抗方案在全人群中的 PFS 表现与赛沃替尼组合在 Met 高异常水平的患者中的数据近似,但考虑赛沃替尼方案为口服给药,且 TEAE 更低,依从性方面具备优势;c) Dato-Dxd 在三代 EGFR TKI 耐药患者中的 ORR、PFS 均不及赛沃替尼联合奥希替尼。
行业数据
原图定位
当前图表所属:
和黄医药-港股公司研究报告-蓝海扬帆行致远海外市场启新程-241230(57页).pdf
表现金流量
呋喹替尼:风险调整销售预测(国内)
和黄医药:管理费用拆分及对应费用率
和黄医药:销售费用拆分及对应费用率
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》